Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

13 Sep 2010 13:45

RNS Number : 5814S
Nomura Code Securities Limited
13 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

10 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.0

563,377

0.2

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

0.0

563,377

0.2

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord shares

Purchase

35,000

11.5 p

Total

Purchases:

35,000

Ord shares

Sale

428,449

11.67 p

Total

Sales:

428,449

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

13 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUOSURRSAKAAR
Date   Source Headline
23rd Jul 20205:02 pmRNSResults of EGM
22nd Jul 20204:29 pmRNSHolding(s) in Company
22nd Jul 20204:24 pmRNSHolding(s) in Company
21st Jul 20207:00 amRNSSilence Therapeutics to Participate in Conferences
16th Jul 20207:00 amRNSMallinckrodt Exercise of Options
2nd Jul 202010:50 amRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCircular and notice of general meeting
30th Jun 202012:39 pmRNSHolding(s) in Company
29th Jun 20204:55 pmRNSHolding(s) in Company
23rd Jun 20207:00 amRNSBusiness Update
23rd Jun 20207:00 amRNSSubmission of Registration Statement to the US SEC
10th Jun 20205:58 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSResults of AGM
5th Jun 20204:33 pmRNSHolding(s) in Company
1st Jun 20204:19 pmRNSAdditional Listing
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20209:37 amRNSPDMR Shareholding
21st May 20204:28 pmRNSGrant of Share Options
20th May 20207:00 amRNSNASDAQ Intention to List
20th May 20207:00 amRNSBroker Appointment
20th May 20207:00 amRNSCompany Update
14th May 20207:00 amRNSParticipation at RBC Virtual Healthcare Conference
12th May 20204:12 pmRNSHolding(s) in Company
12th May 20209:30 amRNSPDMR Dealing
7th May 20207:00 amRNSNotice of AGM
20th Apr 20203:28 pmRNSAdditional listing – correction
20th Apr 20207:00 amRNSPDMR Dealing and Additional Listing
17th Apr 20209:34 amEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
16th Apr 20207:00 amRNSSilence Therapeutics publication of Annual Report
14th Apr 20207:00 amRNSFinal results year ended 31 December 2019
9th Apr 20207:00 amRNSSilence Announces COVID-19 Partnership
2nd Apr 20207:00 amRNSPresentation at Conference and Notice of Results
1st Apr 20204:12 pmRNSAdditional Listing
31st Mar 202011:51 amRNSHolding(s) in Company
30th Mar 20203:00 pmRNSHolding(s) in Company
25th Mar 20202:56 pmEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
25th Mar 20207:01 amRNSR&D Update
25th Mar 20207:00 amRNSCollaboration with AstraZeneca
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Mar 202012:07 pmRNSSecond Price Monitoring Extn
17th Mar 202012:02 pmRNSPrice Monitoring Extension
13th Mar 202012:07 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20201:23 pmRNSHolding(s) in Company
2nd Mar 202012:24 pmRNSHolding(s) in Company
19th Feb 20209:14 amRNSHolding(s) in Company
18th Feb 20207:03 amRNSSilence to Present at Cowen Health Care Conference
17th Feb 202010:00 amRNSSilence Launches Scientific Advisory Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.